VASP

VASP. Vasodilator-stimulated phosphoprotein is a crucial actin regulatory protein involved in controlling cytoskeleton dynamics and cell motility. It is a member of the Ena/VASP homology (EVH) protein family and functions as a central adaptor and anti-capping factor during actin polymerization. Its activity is finely regulated by cyclic nucleotide-dependent protein kinases, such as PKA and PKG, linking cellular signaling directly to structural remodeling.

Overview

VASP was first identified as a major substrate for cAMP- and cGMP-dependent protein kinases in human platelets following stimulation with vasodilators like prostaglandin E1. The protein is encoded by the *VASP* gene located on chromosome 19 in humans. It is ubiquitously expressed but is particularly abundant in cells with high motility requirements, including vascular endothelial cells, fibroblasts, and neurons. Structurally, VASP contains several conserved domains: an N-terminal EVH1 domain that mediates protein-protein interactions by binding to proline-rich motifs, a central proline-rich region, and a C-terminal EVH2 domain essential for F-actin binding and tetramerization.

Function and Mechanism

The primary function of VASP is to promote the elongation of actin filaments by antagonizing the activity of capping proteins that block filament growth. It achieves this by recruiting profilin-bound G-actin monomers to the rapidly growing barbed ends of filaments. The EVH1 domain targets VASP to specific subcellular locations by interacting with ligands such as zyxin, vinculin, and lamellipodin at focal adhesions and leading edges. Phosphorylation by PKA or PKG at specific serine residues (Ser157, Ser239, Thr278) modulates its cellular localization, actin-binding affinity, and interactions with other cytoskeletal proteins, integrating signals from second messengers into directed cell movement.

Clinical Significance

Dysregulation of VASP phosphorylation or expression is implicated in several pathological conditions. In the cardiovascular system, altered VASP function affects platelet aggregation and vascular smooth muscle cell migration, contributing to atherosclerosis, thrombosis, and restenosis. Its role in cell adhesion and motility also links it to cancer metastasis, as its expression can influence tumor cell invasion. Furthermore, VASP is involved in the intracellular life cycle of certain pathogens; for instance, Listeria monocytogenes exploits the host VASP protein to propel itself through the cytoplasm via actin-based motility, a process critical for its virulence.

Genetics

The human *VASP* gene is located on the long arm of chromosome 19 (19q13.2). It consists of 13 exons spanning approximately 10 kilobases of genomic DNA. Several single nucleotide polymorphisms (SNPs) within the gene have been identified, some of which are associated with variations in platelet reactivity and altered risk for cardiovascular events. Studies using gene knockout mice have been instrumental in understanding its physiological role; *VASP*-deficient mice exhibit enhanced platelet activation and a pronounced vascular smooth muscle cell migration phenotype, highlighting its role as a negative regulator of these processes.

Research and Therapeutic Implications

VASP serves as a valuable biomarker for the bioactivity of antiplatelet drugs, particularly those targeting the P2Y12 receptor like clopidogrel. The degree of VASP phosphorylation is measured clinically using flow cytometry-based assays to monitor platelet inhibition in patients. In cancer research, modulating VASP activity is being explored as a potential strategy to inhibit tumor cell dissemination. Ongoing research also investigates its role in neurological disorders involving synaptic plasticity and in wound healing processes. The development of small molecules that specifically target VASP interactions or phosphorylation states represents a promising therapeutic avenue for managing thrombotic disorders and metastatic disease. Category:Proteins Category:Cell biology